TD Cowen Maintains Buy on Caris Life Sciences, Raises Price Target to $38
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
TD Cowen analyst Dan Brennan maintains Caris Life Sciences (NASDAQ:CAI) with a Buy and raises the price target from $36 to $38.
TD Cowen analyst Dan Brennan maintains Caris Life Sciences (NASDAQ:CAI) with a Buy and raises the price target from $36 to $38.